Identification of phenotypes in paediatric patients with acute respiratory distress syndrome: a latent class analysis.


Journal

The Lancet. Respiratory medicine
ISSN: 2213-2619
Titre abrégé: Lancet Respir Med
Pays: England
ID NLM: 101605555

Informations de publication

Date de publication:
03 2022
Historique:
received: 27 05 2021
revised: 04 08 2021
accepted: 09 08 2021
pubmed: 10 12 2021
medline: 22 3 2022
entrez: 9 12 2021
Statut: ppublish

Résumé

Previous latent class analysis of adults with acute respiratory distress syndrome (ARDS) identified two phenotypes, distinguished by the degree of inflammation. We aimed to identify phenotypes in children with ARDS in whom developmental differences might be important, using a latent class analysis approach similar to that used in adults. This study was a secondary analysis of data aggregated from the Randomized Evaluation of Sedation Titration for Respiratory Failure (RESTORE) clinical trial and the Genetic Variation and Biomarkers in Children with Acute Lung Injury (BALI) ancillary study. We used latent class analysis, which included demographic, clinical, and plasma biomarker variables, to identify paediatric ARDS (PARDS) phenotypes within a cohort of children included in the RESTORE and BALI studies. The association of phenotypes with clinically relevant outcomes and the performance of paediatric data in adult ARDS classification algorithms were also assessed. 304 children with PARDS were included in this secondary analysis. Using latent class analysis, a two-class model was a better fit for the cohort than a one-class model (p<0·001). Latent class analysis identified two classes: class 1 (181 [60%] of 304 patients with PARDS) and class 2 (123 [40%] of 304 patients with PARDS), referred to as phenotype 1 and 2 hereafter. Phenotype 2 was characterised by higher concentrations of inflammatory biomarkers, a higher incidence of vasopressor use, and more frequent diagnosis of sepsis, consistent with the adult hyperinflammatory phenotype. All levels of severity of PARDS were observed across both phenotypes. Children with the hyperinflammatory phenotype (phenotype 2) had worse clinical outcomes than those with the hypoinflammatory phenotype (phenotype 1), with a longer duration of mechanical ventilation (median 10·0 days [IQR 6·3-21·0] for phenotype 2 vs 6·6 days [4·1-10·8] for phenotype 1, p<0·0001), and higher incidence of mortality (17 [13·8%] of 123 patients vs four [2·2%] of 181 patients, p=0·0001). When using adult phenotype classification algorithms in children, the soluble tumour necrosis factor receptor-1 (sTNFr1), vasopressor use, and interleukin (IL)-6 variables gave an area under the curve (AUC) of 0·956, and the sTNFr1, vasopressor use, and IL-8 variables gave an AUC of 0·954, compared with the gold standard of latent class analysis. Latent class analysis identified two phenotypes in children with ARDS with characteristics similar to those in adults, including worse outcomes among patients with the hyperinflammatory phenotype. PARDS phenotypes should be considered in design and analysis of future clinical trials in children. US National Institutes of Health.

Sections du résumé

BACKGROUND
Previous latent class analysis of adults with acute respiratory distress syndrome (ARDS) identified two phenotypes, distinguished by the degree of inflammation. We aimed to identify phenotypes in children with ARDS in whom developmental differences might be important, using a latent class analysis approach similar to that used in adults.
METHODS
This study was a secondary analysis of data aggregated from the Randomized Evaluation of Sedation Titration for Respiratory Failure (RESTORE) clinical trial and the Genetic Variation and Biomarkers in Children with Acute Lung Injury (BALI) ancillary study. We used latent class analysis, which included demographic, clinical, and plasma biomarker variables, to identify paediatric ARDS (PARDS) phenotypes within a cohort of children included in the RESTORE and BALI studies. The association of phenotypes with clinically relevant outcomes and the performance of paediatric data in adult ARDS classification algorithms were also assessed.
FINDINGS
304 children with PARDS were included in this secondary analysis. Using latent class analysis, a two-class model was a better fit for the cohort than a one-class model (p<0·001). Latent class analysis identified two classes: class 1 (181 [60%] of 304 patients with PARDS) and class 2 (123 [40%] of 304 patients with PARDS), referred to as phenotype 1 and 2 hereafter. Phenotype 2 was characterised by higher concentrations of inflammatory biomarkers, a higher incidence of vasopressor use, and more frequent diagnosis of sepsis, consistent with the adult hyperinflammatory phenotype. All levels of severity of PARDS were observed across both phenotypes. Children with the hyperinflammatory phenotype (phenotype 2) had worse clinical outcomes than those with the hypoinflammatory phenotype (phenotype 1), with a longer duration of mechanical ventilation (median 10·0 days [IQR 6·3-21·0] for phenotype 2 vs 6·6 days [4·1-10·8] for phenotype 1, p<0·0001), and higher incidence of mortality (17 [13·8%] of 123 patients vs four [2·2%] of 181 patients, p=0·0001). When using adult phenotype classification algorithms in children, the soluble tumour necrosis factor receptor-1 (sTNFr1), vasopressor use, and interleukin (IL)-6 variables gave an area under the curve (AUC) of 0·956, and the sTNFr1, vasopressor use, and IL-8 variables gave an AUC of 0·954, compared with the gold standard of latent class analysis.
INTERPRETATION
Latent class analysis identified two phenotypes in children with ARDS with characteristics similar to those in adults, including worse outcomes among patients with the hyperinflammatory phenotype. PARDS phenotypes should be considered in design and analysis of future clinical trials in children.
FUNDING
US National Institutes of Health.

Identifiants

pubmed: 34883088
pii: S2213-2600(21)00382-9
doi: 10.1016/S2213-2600(21)00382-9
pmc: PMC8897230
mid: NIHMS1762568
pii:
doi:

Types de publication

Journal Article Randomized Controlled Trial Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

289-297

Subventions

Organisme : NHLBI NIH HHS
ID : U01 HL086622
Pays : United States
Organisme : NICHD NIH HHS
ID : R21 HD097387
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL095410
Pays : United States
Organisme : NHLBI NIH HHS
ID : R35 HL140026
Pays : United States
Organisme : NIGMS NIH HHS
ID : R35 GM142992
Pays : United States

Investigateurs

Michael A Matthay (MA)
Scot T Bateman (ST)
Marc D Berg (MD)
Santiago Borasino (S)
Gokul K Bysani (GK)
Allison S Cowl (AS)
Cindy D Bowens (CD)
Vincent S Faustino (VS)
Lori D Fineman (LD)
Aaron J Godshall (AJ)
Eliotte L Hirshberg (EL)
Aileen L Kirby (AL)
Gwenn E McLaughlin (GE)
Shivanand S Medar (SS)
Phineas P Oren (PP)
James B Schneider (JB)
Adam J Schwarz (AJ)
Thomas P Shanley (TP)
Lauren R Source (LR)
Edward J Truemper (EJ)
Michele A Vender Heyden (MA)
Kimberly Wittmayer (K)
Athena F Zuppa (AF)
David Wypij (D)

Informations de copyright

Copyright © 2022 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests MKD, MZ, MAQC, AS, KLD, and HF report grants from the US National Institutes of Health. CSC reports grants from the US National Institutes of Health, Roche/Genentech, Bayer, and Quantum Leap Healthcare Collaborative; and consultancy fees from Quark Pharmaceuticals, Prometic, Gen1e Life Sciences, and Vasomune. MWQ reports consultancy fees from Mitchell Leeds, Tanoury, Nauts, and McKinney and Barbarino. All other authors declare no competing interests.

Références

Lancet Respir Med. 2019 Feb;7(2):115-128
pubmed: 30361119
Crit Care Med. 2018 Jan;46(1):e9-e16
pubmed: 28991832
Am J Respir Crit Care Med. 2021 Jun 15;203(12):1449-1451
pubmed: 33565943
Am J Respir Crit Care Med. 2016 Jul 1;194(1):58-66
pubmed: 26796541
Crit Care Med. 2021 Jan 1;49(1):e63-e79
pubmed: 33165028
Pediatr Crit Care Med. 2012 Jan;13(1):e48-50
pubmed: 21057365
Pediatr Crit Care Med. 2015 Jun;16(5 Suppl 1):S23-40
pubmed: 26035358
Am J Respir Crit Care Med. 2015 Nov 1;192(9):1045-51
pubmed: 26177009
Am J Respir Crit Care Med. 2017 Feb 1;195(3):331-338
pubmed: 27513822
Pediatr Crit Care Med. 2015 Jun;16(5):428-39
pubmed: 25647235
Lancet Respir Med. 2020 Mar;8(3):247-257
pubmed: 31948926
JAMA. 2016 Feb 23;315(8):788-800
pubmed: 26903337
Crit Care Med. 2002 Aug;30(8):1772-7
pubmed: 12163791
Pediatr Crit Care Med. 2019 Feb;20(2):110-112
pubmed: 30720645
Am J Respir Crit Care Med. 2005 May 1;171(9):995-1001
pubmed: 15618461
Lancet Respir Med. 2018 Sep;6(9):691-698
pubmed: 30078618
Thorax. 2018 May;73(5):439-445
pubmed: 29477989
Lancet Respir Med. 2014 Aug;2(8):611-20
pubmed: 24853585
Intensive Care Med. 2018 Nov;44(11):1859-1869
pubmed: 30291376
Am J Respir Crit Care Med. 2016 Jul 15;194(2):147-55
pubmed: 27244481
JAMA. 2015 Jan 27;313(4):379-89
pubmed: 25602358
Am J Respir Crit Care Med. 2021 Jun 15;203(12):1503-1511
pubmed: 33465019
Pediatr Crit Care Med. 2018 Oct;19(10):930-938
pubmed: 30095747

Auteurs

Mary K Dahmer (MK)

Department of Pediatrics, Division of Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA. Electronic address: mkdahmer@umich.edu.

Guangyu Yang (G)

Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA.

Min Zhang (M)

Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA.

Michael W Quasney (MW)

Department of Pediatrics, Division of Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA.

Anil Sapru (A)

Department of Pediatrics, University of California, Los Angeles, Los Angeles, CA, USA.

Heidi M Weeks (HM)

Department of Nutritional Sciences, University of Michigan, Ann Arbor, MI, USA.

Pratik Sinha (P)

Department of Anesthesia, Washington University, St Louis, MO, USA.

Martha A Q Curley (MAQ)

Department of Family and Community Health (School of Nursing), Division of Anesthesia and Critical Care Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Research Institute, Children's Hospital of Philadelphia, Philadelphia, PA.

Kevin L Delucchi (KL)

Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, San Francisco, CA, USA.

Carolyn S Calfee (CS)

Department of Medicine, Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, University of California, San Francisco, San Francisco, CA, USA.

Heidi Flori (H)

Department of Pediatrics, Division of Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH